Nephros Statistics
Total Valuation
Nephros has a market cap or net worth of $36.25 million. The enterprise value is $33.50 million.
| Market Cap | 36.25M |
| Enterprise Value | 33.50M |
Important Dates
The next confirmed earnings date is Thursday, August 7, 2025, after market close.
| Earnings Date | Aug 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Nephros has 10.60 million shares outstanding. The number of shares has increased by 1.85% in one year.
| Current Share Class | 10.60M |
| Shares Outstanding | 10.60M |
| Shares Change (YoY) | +1.85% |
| Shares Change (QoQ) | +0.57% |
| Owned by Insiders (%) | 12.80% |
| Owned by Institutions (%) | 44.05% |
| Float | 9.24M |
Valuation Ratios
The trailing PE ratio is 45.04 and the forward PE ratio is 763.23.
| PE Ratio | 45.04 |
| Forward PE | 763.23 |
| PS Ratio | 2.33 |
| Forward PS | 3.13 |
| PB Ratio | 3.90 |
| P/TBV Ratio | 4.54 |
| P/FCF Ratio | 81.10 |
| P/OCF Ratio | 72.22 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 36.61, with an EV/FCF ratio of 74.94.
| EV / Earnings | 41.82 |
| EV / Sales | 2.16 |
| EV / EBITDA | 36.61 |
| EV / EBIT | 43.39 |
| EV / FCF | 74.94 |
Financial Position
The company has a current ratio of 5.92, with a Debt / Equity ratio of 0.14.
| Current Ratio | 5.92 |
| Quick Ratio | 4.45 |
| Debt / Equity | 0.14 |
| Debt / EBITDA | 0.91 |
| Debt / FCF | 2.97 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 9.17% and return on invested capital (ROIC) is 4.71%.
| Return on Equity (ROE) | 9.17% |
| Return on Assets (ROA) | 4.16% |
| Return on Invested Capital (ROIC) | 4.71% |
| Return on Capital Employed (ROCE) | 7.52% |
| Revenue Per Employee | $500,548 |
| Profits Per Employee | $25,839 |
| Employee Count | 31 |
| Asset Turnover | 1.34 |
| Inventory Turnover | 2.46 |
Taxes
In the past 12 months, Nephros has paid $15,000 in taxes.
| Income Tax | 15,000 |
| Effective Tax Rate | 1.84% |
Stock Price Statistics
The stock price has increased by +57.99% in the last 52 weeks. The beta is 1.11, so Nephros's price volatility has been higher than the market average.
| Beta (5Y) | 1.11 |
| 52-Week Price Change | +57.99% |
| 50-Day Moving Average | 3.60 |
| 200-Day Moving Average | 2.13 |
| Relative Strength Index (RSI) | 44.68 |
| Average Volume (20 Days) | 23,151 |
Short Selling Information
The latest short interest is 3,779, so 0.04% of the outstanding shares have been sold short.
| Short Interest | 3,779 |
| Short Previous Month | 3,569 |
| Short % of Shares Out | 0.04% |
| Short % of Float | 0.04% |
| Short Ratio (days to cover) | 0.06 |
Income Statement
In the last 12 months, Nephros had revenue of $15.52 million and earned $801,000 in profits. Earnings per share was $0.08.
| Revenue | 15.52M |
| Gross Profit | 9.69M |
| Operating Income | 772,000 |
| Pretax Income | -1.29M |
| Net Income | 801,000 |
| EBITDA | 915,000 |
| EBIT | 772,000 |
| Earnings Per Share (EPS) | $0.08 |
Balance Sheet
The company has $4.08 million in cash and $1.33 million in debt, giving a net cash position of $2.75 million or $0.26 per share.
| Cash & Cash Equivalents | 4.08M |
| Total Debt | 1.33M |
| Net Cash | 2.75M |
| Net Cash Per Share | $0.26 |
| Equity (Book Value) | 9.29M |
| Book Value Per Share | 0.88 |
| Working Capital | 7.47M |
Cash Flow
In the last 12 months, operating cash flow was $502,000 and capital expenditures -$55,000, giving a free cash flow of $447,000.
| Operating Cash Flow | 502,000 |
| Capital Expenditures | -55,000 |
| Free Cash Flow | 447,000 |
| FCF Per Share | $0.04 |
Margins
Gross margin is 62.45%, with operating and profit margins of 4.98% and 5.16%.
| Gross Margin | 62.45% |
| Operating Margin | 4.98% |
| Pretax Margin | 5.26% |
| Profit Margin | 5.16% |
| EBITDA Margin | 5.90% |
| EBIT Margin | 4.98% |
| FCF Margin | 2.88% |
Dividends & Yields
Nephros does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.85% |
| Shareholder Yield | -1.85% |
| Earnings Yield | 2.21% |
| FCF Yield | 1.23% |
Analyst Forecast
The average price target for Nephros is $5.00, which is 44.51% higher than the current price. The consensus rating is "Buy".
| Price Target | $5.00 |
| Price Target Difference | 44.51% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on July 10, 2019. It was a reverse split with a ratio of 1:9.
| Last Split Date | Jul 10, 2019 |
| Split Type | Reverse |
| Split Ratio | 1:9 |
Scores
Nephros has an Altman Z-Score of -10.2 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -10.2 |
| Piotroski F-Score | 6 |